MedTrace Logo

Multiple Ascending Doses (MAD) of AZD3199 Given Once Daily as Inhaled Formulation Via Turbuhaler to Healthy Men

NCT00713271 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2014-04-10

No results posted yet for this study

Summary

The purpose of this study is to investigate the safety and tolerability of multiple once daily ascending doses of AZD3199 in healthy men

Conditions

  • Healthy Volunteers

Interventions

DRUG

AZD3199

Low dose Dry powder for inhalation, o.d., 1+12 days

DRUG

Placebo

DRUG

AZD3199

intermediate dose Dry powder for inhalation, o.d., 1+12 days

DRUG

AZD3199

high dose Dry powder for inhalation, o.d., 1+12 days

Sponsors & Collaborators

Principal Investigators

  • Gabriella Samuelsson Palmgren · AZ CPU Lund, Sweden

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-08-31
Primary Completion
2008-11-30
Completion
2008-11-30

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00713271 on ClinicalTrials.gov